Kairos Pharma (KAPA) Amortizatization of Intangibles (2023 - 2024)
Kairos Pharma's (KAPA) quarterly Amortizatization of Intangibles came in at $115000.0 in Q3 2024, up 1050.0% YoY from $10000.0 in Q4 2023, and up 505.26% on a QoQ basis from $19000.0 in Q2 2024.
Kairos Pharma (KAPA) Amortizatization of Intangibles (2023 - 2024) Analysis & Trends
Kairos Pharma (KAPA) has 2 years of Amortizatization of Intangibles data on file, last reported at $115000.0 in Q3 2024.
- Quarterly Amortizatization of Intangibles rose 1050.0% year-over-year to $115000.0 in Q3 2024, while the trailing twelve-month figure through Dec 2024 was $160000.0 (changed N/A YoY) and the FY2024 annual result came in at $154000.0, up 175.0% from the prior year.
- Amortizatization of Intangibles rose to $115000.0 in Q3 2024, from $19000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $115000.0 in Q3 2024 to a low of $10000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kairos Pharma | 5.39 Mn | 55,970.58 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 115,000.00 |
| Sep 30, 2024 | 115,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Dec 31, 2023 | 26,000.00 |
| Dec 31, 2023 | 26,000.00 |
| Sep 30, 2023 | 10,000.00 |
| Sep 30, 2023 | 10,000.00 |